• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Aaron's

Aaron's

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. New Data at AAN Reinforce Clinical Benefit of Genentech’s OCREVUS (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis

    New Data at AAN Reinforce Clinical Benefit of Genentech’s OCREVUS (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis

  2. Genentech to Present New Data at AAN Reinforcing Efficacy and Safety of Newly FDA Approved OCREVUS (Ocrelizumab) in Two Types of Multiple Sclerosis

    Genentech to Present New Data at AAN Reinforcing Efficacy and Safety of Newly FDA Approved OCREVUS (Ocrelizumab) in Two Types of Multiple Sclerosis

  3. Wolters Kluwer Showcases Innovative Culture and Software Development Prowess with 4th Annual Code Games Event

    Wolters Kluwer Showcases Innovative Culture and Software Development Prowess with 4th Annual Code Games Event

  4. INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Aaron’s, Inc. Investors

    INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Aaron’s, Inc. Investors

  5. TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early MS Treatment

    TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early MS Treatment

  6. GenSight Biologics to Present GS010 At the 2017 Annual Meeting of the American Association of Neurology

    GenSight Biologics to Present GS010 At the 2017 Annual Meeting of the American Association of Neurology

  7. Small-Cap Names That Are Big With Medalist Funds

    Among the thousands of small-company stocks, these are the most popular among analyst-recommended small-cap funds.

  8. Waiting to Pull Up Anchor

    Small caps have reached the top of their cycle, manager Eric Cinnamond says. He’s hoarding cash for when the market turns.

©2017 Morningstar Advisor. All right reserved.